PSTV PLUS THERAPEUTICS, INC.
Price Chart
Executive Summary
The SEC declared Plus Therapeutics' Form S-3 shelf registration (File No. 333-296411) effective on June 5, 2026. This shelf, covering common stock, preferred stock, debt securities, warrants, and units, includes an at-the-market (ATM) facility with Canaccord Genuity. The effectiveness opens the door for potential future capital raises, creating an ongoing dilution overhang for the company's $37M market cap stock.
Actionable Insight
Monitor for a prospectus supplement or 8-K announcing an actual ATM draw or shelf takedown — that will be the material catalyst. Until then, the effective shelf creates an overhang that may cap upside. Watch for any secondary offering pricing below current market levels.
Key Facts
- EFFECT notice for S-3 shelf registration (File No. 333-296411) declared effective by SEC on June 5, 2026.
- Shelf covers common stock, preferred stock, debt securities, warrants, and units with an unspecified maximum aggregate offering amount.
- Original S-3/A included an Equity Distribution Agreement with Canaccord Genuity LLC for an at-the-market (ATM) common stock facility.
- Company's market cap is approximately $37M, making even moderate ATM draws potentially dilutive.
- Cross-filing: S-1 IPO registration filed 150 days ago suggests the company has been pursuing multiple capital pathways.
Financial Impact
Potential dilution from future ATM sales or shelf takedowns; no specific offering size or pricing disclosed. Company market cap of $37M amplifies dilution risk from any moderate raise.
Risk Factors
- ATM equity sales could dilute existing shareholders significantly given the small market cap.
- Combined with prior S-1 IPO registration, multiple capital pathways suggest ongoing cash needs.
- No revenue or cash runway details in the EFFECT filing — unknowns about the urgency of capital raising.
Market Snapshot
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-001913 |
| Document: 9999999995-26-001913-index.html | 9999999995-26-001913 |
| Document: 9999999995-26-001913.txt | 9999999995-26-001913 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
2d ago
|
EFFECT
| $5.38 awaiting T+5 | awaiting T+5 | — | $5.39 (−0.19%) |
|
Jun 5, 2026
5d ago
|
S-3/A
| $5.60 awaiting T+5 | awaiting T+5 | — | $5.39 (−3.75%) |
|
May 19, 2026
22d ago
|
Press Release
| $5.83 $6.70 | ▲ +14.92% | ▲ +12.68% | $5.39 (−7.55%) |
|
May 15, 2026
26d ago
|
Press Release
| $5.84 $6.60 | ▼ −13.01% | ▼ −11.40% | $5.39 (+7.71%) |
|
May 8, 2026
4w ago
|
Press Release
| $6.12 $5.76 | ▼ −5.88% | ▼ −7.35% | $5.39 (−11.93%) |
|
Apr 28, 2026
6w ago
|
Press Release
| $5.95 $6.30 | ▲ +5.88% | ▲ +4.19% | $5.39 (−9.41%) |
|
Apr 21, 2026
7w ago
|
8-K
| $7.14 $5.95 | ▼ −16.67% | ▼ −17.75% | $5.39 (−24.51%) |
|
Apr 9, 2026
8w ago
|
8-K
| $3.92 $5.95 | ▲ +51.79% | ▲ +48.60% | $5.39 (+37.50%) |
|
Apr 8, 2026
9w ago
|
8-K
| $3.17 $5.65 | ▲ +78.23% | ▲ +74.72% | $5.39 (+70.03%) |
|
Apr 2, 2026
9w ago
|
Press Release
| $3.56 $4.80 | ▲ +34.83% | ▲ +31.21% | $5.39 (+51.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access